GlassScriptPhysician profile
Roxanne D Chalifoux
NPI 1164074761
$1,273.23
in general payments reported to CMS, 2019-2025
12 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $128 · 2021: $123 · 2022: $238 · 2023: $270 · 2024: $283 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $416.07 | 2023-2025 | Rocklatan, Simbrinza, Rhopressa |
| Allergan, INC. | $270.00 | 2020-2022 | |
| Abbvie INC. | $181.04 | 2023-2025 | Durysta |
| Johnson & Johnson Vision Care, INC. | $123.12 | 2021 | |
| Coopervision INC. | $78.00 | 2020 | |
| Bausch & Lomb Americas INC. | $50.75 | 2024 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $44.65 | 2025 | |
| Oyster Point Pharma, INC. | $26.81 | 2024 | Tyrvaya |
| Thea Pharma INC. | $24.23 | 2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $22.61 | 2025 | Xdemvy |
| Dompe US, INC. | $18.03 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $17.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Chalifoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.